DUBLIN--(BUSINESS WIRE)--The "2018 Celiac (Coeliac) Disease Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
Celiac Disease pipeline comprises of 24 active drugs under active development as of April 2018. Of these, 4 drugs are in Phase 1 and 4 drugs in phase 2. None of the drugs have progressed to Phase 3. Further, 12 drugs are in Pre-clinical stage, 4 drugs in research/discovery stages.
42 companies are developing the pipeline for Celiac Disease. Of this, Takeda Pharmaceutical, ImmunogenX, Innovate Biopharmaceuticals and Amgen have the most advanced compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is Immunomodulators.
This report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Pre-eclampsia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Pre-eclampsia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
- Amgen Inc.
- Amyra Biotech AG
- Antolrx, Inc.
- Bioniz, LLC
- Calypso Biotech SA
- Circle33 LLC
- Cour Pharmaceutical Development Company, Inc
- F. Hoffmann La-Roche AG
- Immunogenx, LLC
- Immusant Inc
- Innovate Biopharmaceuticals, Inc
- Intrexon Corp
- Kanyos Bio, Inc.
- Ligand Pharmaceuticals
- Provid Pharmaceuticals, Inc
- PVP Biologics, Inc
- Selecta Biosciences Inc.
- Sigmoid Pharma Limited
- Synthetic Biologics, Inc.
- Takeda Pharmaceutical Company Ltd
- Topas Therapeutics GmbH
- Vactech OY
- Zedira Gmbh
Key Topics Covered
1. Table of Contents
2 Executive Summary
3 Celiac Disease - Company-wise Pipeline Analysis
4 Celiac Disease Drug Snapshots
5 Recent Developments in Celiac Disease Pipeline
For more information about this report visit https://www.researchandmarkets.com/research/jtqhpg/2018_celiac?w=4